Central Nervous System Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.02 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Central Nervous System Therapeutics Market Analysis
The Global Central Nervous System Therapeutics Market size is expected to grow from USD 112,884.87 million in 2023 to USD 151,208.00 million by 2028, at a CAGR of 6.02% during the forecast period.
COVID-19 cases worldwide profoundly impacted the CNS therapeutics market as lockdown restrictions created few mental disturbances in people. For instance, according to a research brief published by the WHO in March 2022, anxiety and sadness surged dramatically worldwide by 25% in the first year of the COVID-19 pandemic. The increase in the prevalence of mental health problems coincided with severe disruptions to mental health services, leaving huge gaps in care and adversely impacting the studied market during the pandemic. Further, as per the source mentioned above, by the end of 2021, things will have somewhat improved, but still, far too many people are unable to get the care and support they need for both current and newly developed mental health illnesses, thereby adversely impacting the market over the post-pandemic period.
An increase in the number of patients suffering from central nervous system (CNS) diseases such as mental health and neurodegenerative diseases and other CNS diseases increases the usage of CNS therapeutics which is expected to drive the market's growth. For instance, according to the March 2023 World Health Organization (WHO) report, more than 55 million people have dementia worldwide, and nearly 10 million new cases are reported yearly. As per the same source, Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia. Similarly, as per the report published by Ridgecrest Regional Hospital in May 2022, one billion people globally, or 12% of the world's population, suffer from migraines. In addition, there is a massive demand for CNS therapeutics, and government and non-government entities are raising funds to support the authorization of CNS therapeutics, which is expected to fuel the growth in the market. For instance, in May 2022, Minoryx raised USD 55.4 USD million (EUR 51 million) to support marketing authorization applications and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy for orphan central nervous system (CNS) disorders. Hence, the high prevalence of CNS diseases likely increases the demand for therapeutics and new developments, which are expected to boost growth in the studied market.
The development of novel drug delivery systems is expected to increase the usage of various neurological drugs through these systems, which will likely propel the market to grow. For instance, in January 2023, Spark Therapeutics and Neurochase entered a strategic collaboration to develop Neurochase's proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Through this collaboration, Neurochase will bring its deep direct drug delivery technology expertise to Spark's leading AAV platform, which is expected to grow significantly in the studied market over the forecast period.
Therefore, the high burden of CNS diseases, increasing demand for CNS therapeutics, and the development of novel drug delivery systems likely increase the need for the market products and are expected to boost the market over the forecast period. However, high research and development expenditure in developing CNS therapeutics and adverse reactions associated with them are expected to restrain the growth of the studied market over the forecast period.
Central Nervous System Therapeutics Market Trends
Parkinson's Disease Under Degenerative Disease Segment is Expected to Have Major Market Share Over the Forecast Period
Parkinson's disease is a degenerative disease that affects the nervous system and body parts controlled by the nerves. The degenerative disease occurs when nerve cells in the brain and peripheral nervous systems lose their function and die. The Parkinson's disease segment is expected to have a significant market share over the forecast period attributed to the increasing prevalence of Parkinson's disease and increasing research and developments on new therapeutics for this disease.
According to the report by Parkinson's Foundation published in December 2022, nearly 90,000 people in the United States are diagnosed with Parkinson's disease (PD) each year, representing a 50% increase from the previous estimate of 60,000 diagnosed yearly. In addition, as per the source mentioned above, the number of people living with Parkinson's is expected to rise to 1.2 million by 2030 in the United States. This data shows the increasing burden of Parkinson's disease, which increase the demand for therapeutics that likely propel the market over the forecast period.
Moreover, the new product approvals and launches in this segment increase the widespread distribution of products in various regions and increase the availability of products which is expected to boost the segment's growth. For instance, in February 2021, Eisai Co., Ltd launched the Parkinson's disease treatment Equfina (safinamide mesylate) in the Asian region, excluding Japan. Such product approvals and launches are expected to drive the segment's growth over the forecast period.
Thus, all the factors mentioned above, such as the increasing burden of Parkinson's disease and new product developments, along with approvals and launches, are expected to boost the market's growth over the forecast period.
North America is Expected to Have a Significant Share in the Market Over the Forecast Period
North America is expected to have a significant share in the market over the forecast period owing to the growth of technology in the pharmaceutical sector that helps in new drug developments, increasing product launches, the rising burden of central nervous system diseases, and the rising level of research and developments in the countries like the United States and Canada.
According to the Alzheimer's Disease Facts and Figures 2023 published by Alzheimer's Association, an estimated 6.7 million Americans age 65 and older will be living with Alzheimer's dementia in 2023, and the number is expected to increase due to the rising geriatric population in the region. Similarly, the high prevalence of CNS diseases increases the demand for therapeutics. For instance, in a Statistics Canada study published in 2021, about one in five Canadians aged 12 and older said they required some help with their mental health. Furthermore, the prevalence of neurological diseases is expanding, which boosts funding and support for research projects that develop novel treatments and may increase the market's growth. For instance, in August 2022, the National Multiple Sclerosis Society committed USD 19 million to launch 40 new multi-year research awards to drive progress toward stopping multiple sclerosis. Hence, the latest initiative in the region is expected to grow the market over the forecast period.
Furthermore, the new developments and acceptance of regulatory approval for various products likely increase the widespread applications and are expected to grow significantly in the market. For instance, in August 2022, Paladin Labs Inc received acceptance from Health Canada for a New Drug Submission (NDS) application for carbamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional treatment.
Thus, the rising CNS disease burden, new research funding for product development, and increasing regulatory approvals in the region increase the demand for various CNS drugs and are expected to boost the market over the forecast period.
Central Nervous System Therapeutics Industry Overview
The central nervous system therapeutics market is highly competitive, with several market players. However, the need for innovation in the treatment and drug delivery system, clinical trials, and strategic collaboration is likely to help companies maintain their market position. Some of the key companies in the market are Biogen Inc, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Pfizer Inc., and GSK plc, among others.
Central Nervous System Therapeutics Market Leaders
-
Biogen
-
Novartis AG
-
Merck KGaA
-
Eli Lilly and Company
-
Johnson & Johnson
*Disclaimer: Major Players sorted in no particular order
Central Nervous System Therapeutics Market News
- In February 2023, Sage Therapeutics, Inc. and Biogen Inc received acceptance from the United States FDA for a New Drug Application (NDA) application for zuranolone in the treatment of the major depressive disorder (MDD) and postpartum depression (PPD).
- In January 2023, Eisai Co., Ltd. and Biogen Inc. received Accelerated Approval from United States FDA for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ) for the treatment of Alzheimer's disease (AD).
Central Nervous System Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Burden of CNS Disorders
- 4.2.2 Increase in Generic Drugs
- 4.2.3 Development of Novel Drug Delivery Systems
-
4.3 Market Restraints
- 4.3.1 Adverse Events Associated with CNS Therapeutics
- 4.3.2 High R&D Costs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Million)
-
5.1 By Disease
- 5.1.1 Neurovascular Diseases
- 5.1.2 Trauma
- 5.1.3 Mental Health
- 5.1.3.1 Anxiety Disorders
- 5.1.3.2 Epilepsy
- 5.1.3.3 Psychotic Disorders
- 5.1.3.4 Other Mental Health Disorders
- 5.1.4 Degenerative Diseases
- 5.1.4.1 Alzheimer's Disease
- 5.1.4.2 Parkinson's Disease
- 5.1.4.3 Multiple Sclerosis
- 5.1.4.4 Amyotrophic Lateral Sclerosis
- 5.1.4.5 Other Degenerative Diseases
- 5.1.5 Infectious Diseases
- 5.1.6 Cancer
- 5.1.7 Other Diseases
-
5.2 By Drug Class
- 5.2.1 Analgesics
- 5.2.2 Antidepressant
- 5.2.3 Anesthetics
- 5.2.4 Anti-Parkinson Drugs
- 5.2.5 Anti-Epileptics
- 5.2.6 Other Drug Classes
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Biogen
- 6.1.2 Otsuka Pharmaceutical Co. Ltd
- 6.1.3 Eli Lilly and Company
- 6.1.4 Merck KGaA
- 6.1.5 AstraZeneca
- 6.1.6 Takeda Pharmaceutical Coompany Limited
- 6.1.7 Novartis AG
- 6.1.8 Teva Pharmaceutical Industries Ltd
- 6.1.9 Johnson & Johnson
- 6.1.10 Pfizer Inc.
- 6.1.11 GSK plc
- 6.1.12 HANDA PHARMA, INC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCentral Nervous System Therapeutics Industry Segmentation
As per the scope, the central nervous system (CNS) consists of the brain and spinal cord. It controls things like thought, movement, and emotion, as well as breathing, heart rate, hormones, and body temperature. The drugs that act on the functions of the brain and spinal cord are central nervous system therapeutics. The central nervous system therapeutics market is segmented by Disease (Neurovascular Diseases, Trauma, Mental Health, Degenerative Disease, Infectious Diseases, Cancer, and Others), Drug Class (Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Other Drug Classes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Disease | Neurovascular Diseases | |
| Trauma | ||
| Mental Health | Anxiety Disorders | |
| Epilepsy | ||
| Psychotic Disorders | ||
| Other Mental Health Disorders | ||
| Degenerative Diseases | Alzheimer's Disease | |
| Parkinson's Disease | ||
| Multiple Sclerosis | ||
| Amyotrophic Lateral Sclerosis | ||
| Other Degenerative Diseases | ||
| Infectious Diseases | ||
| Cancer | ||
| Other Diseases | ||
| By Drug Class | Analgesics | |
| Antidepressant | ||
| Anesthetics | ||
| Anti-Parkinson Drugs | ||
| Anti-Epileptics | ||
| Other Drug Classes | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Central Nervous System Therapeutics Market Research FAQs
What is the current Global Central Nervous System Therapeutics Market size?
The Global Central Nervous System Therapeutics Market is projected to register a CAGR of 6.02% during the forecast period (2024-2029)
Who are the key players in Global Central Nervous System Therapeutics Market?
Biogen, Novartis AG, Merck KGaA, Eli Lilly and Company and Johnson & Johnson are the major companies operating in the Global Central Nervous System Therapeutics Market.
Which is the fastest growing region in Global Central Nervous System Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Central Nervous System Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Central Nervous System Therapeutics Market.
What years does this Global Central Nervous System Therapeutics Market cover?
The report covers the Global Central Nervous System Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Central Nervous System Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Central Nervous System Therapeutics Industry Report
Statistics for the 2024 Central Nervous System Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Central Nervous System Therapeutics analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
